Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole in Invasive Fungal Infections
NCT00001757Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 1997
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of voriconazole in invasive fungal infection (IFI), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Efficacy. Started Nov 1997; status: completed.
02
Drugs
voriconazole
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT00001757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001757.